Dr. Robert L. Feldman, MD

Dr. Feldman practices at AdventHealth Ocala in Ocala, Florida.

Dr. Feldman's NPI, 1346345550, was assigned on September 13, 2006. Dr. Feldman graduated from Rutgers Robert Wood Johnson Medical School in 1974. Dr. Feldman holds Florida license ME26083.

Dr. Feldman's primary practice is AdventHealth Ocala, at 1500 Sw 1st Ave, Ocala, FL 34471. The practice phone is (352) 351-7282.

Dr. Feldman's primary practice is AdventHealth Ocala in Ocala, Florida. Dr. Feldman is also affiliated with AdventHealth Ocala. The medical group on file is AdventHealth Medical Group Cardiovascular Surgery at Tampa. Dmand AI also links Dr. Feldman to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Feldman practices, 4 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Feldman's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Feldman is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Feldman is licensed in Florida.

Dmand AI lists angioplasty, cardiac catheterization and leg revascularization among the conditions Dr. Feldman treats.

CMS data shows 1,096 Medicare services from Dr. Feldman across 20 procedure codes in 2024, for 264 Medicare patients. Medicare paid $135,102 for them.

CMS counts 264 Medicare patients who saw Dr. Feldman in 2024. The largest group is 75 to 84, with 126 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Feldman's median patient age at 76, with 42% women.

In 2024, Dr. Feldman wrote 375 Medicare Part D claims for 209 patients. 96% of them were for generic drugs. CMS names the drug for 330 of them, across 3 drugs with 11 or more claims each, at $3,661 in total drug cost. In 2023, CMS named 372 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Feldman for performance year 2024, reported as part of a group. Dr. Feldman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 116 procedures of coronary angioplasty and stenting by Dr. Feldman, more than 97% of the clinicians it reports for that procedure.

Leg revascularization (restoring blood flow): 1 to 10 procedures (CMS shows small counts as a range)

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 175 papers to Dr. Feldman, published from 2010 to 2024. 2014 was the busiest year, with 4. The most frequent topics are Coronary Disease, Hemodynamics and Coronary Circulation. Dr. Feldman has published most often in Am J Cardiol. Dr. Feldman's most frequent co-authors are Carl J. Pepine, MD, James A. Hill, MD and Dominic J. Allocco, MD.

Dmand AI links Dr. Feldman to 13 clinical trials. 1 is still active or recruiting. Conditions studied include Peripheral Arterial Disease, Peripheral Vascular Diseases and Alzheimer Disease. Abbott Medical Devices sponsors the most, 2. Open Payments lists research payments to Dr. Feldman that name 3 trials.

CMS Open Payments shows 123 general payments to Dr. Feldman from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 59% of the total. Boston Scientific Corporation paid the most, $21,397. It also lists 7 research payments totaling $8,461 from 2016 to 2018, naming 3 clinical trials.

Dmand AI lists 1 award for Dr. Feldman.

Dr. Feldman graduated from Rutgers Robert Wood Johnson Medical School in 1974. Dr. Feldman is a member of ACC.

Dr. Feldman is in network with 12 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.